Flonoltinib

Flonoltinib is listed on ClinicalTrials.gov as an intervention in 3 registered phase 2 trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, in myeloproliferative neoplasms. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.